Effective Cell Line Development: Reducing Risk, Decreasing Timelines, and Optimizing Outcomes
When it comes to the commercialization of biologics, effective, high-quality cell line development (CLD) is essential for success, but there is no one right way to tackle it. Some companies have extensive in-house capabilities and look for reliable equipment suppliers to help streamline early-stage development and enable a smooth transition to manufacturing. On the other end of the spectrum, certain companies need a fully outsourced solution that can provide cell lines, products, and experienced professionals to oversee the entire CLD project. And others need a hybrid approach for a custom CLD solution that best meets their needs.
The common thread in all of these scenarios is the need for a reliable partner that offers experience, expertise, and a comprehensive portfolio of products and services to help minimize risks and optimize outcomes. A synergistic, single-vendor approach increases collaboration and reduces project management requirements, and overall costs.
This webinar will highlight the key challenges and points to consider during biopharmaceutical CLD and the impact early decision-making can have at later stages of the development process. Join us to explore the advantages and disadvantages of various approaches to CLD and learn about Sartorius’ whole CLD portfolio, which encompasses instruments, cell line development services, technology licenses, cell culture media, and related services.
- Understand a modern cell line development workflow and get insights into the critical steps.
- Review the various approaches to CLD and their advantages and disadvantages.
- Identify the key characteristics to consider when evaluating external providers of CLD products and services.
- Explore Sartorius’ portfolio of CLD products and services and the efficiencies realized from a single-vendor approach.
Meet Our Expert
Christoph Zehe
Research Fellow, Sartorius
Christoph holds a PhD in molecular and cell biology from the University of Heidelberg. In 2007, he joined Cellca GmbH (acquired by Sartorius in 2015), where he established a leading platform technology for the generation of high-expressing cell lines. From 2011 to 2018, he held several R&D positions and is currently a Sartorius Research Fellow focused on technology development in the fields of synthetic, molecular, and cell biology.